Effects of Estrogen and Hot Flashes on Mood in Postmenopausal Women
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
SPECIFIC AIMS (Research Objectives)
To define the relative effects of hot flashes and changes in estradiol on mood in postmenopausal women:
Hypotheses:
- Estrogen treatment has a similar therapeutic effect on mood in women with and without frequent hot flashes
- Estradiol levels correlate with improvement in mood
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy women ≥40 years-old
- Early postmenopausal, defined as:
- No menstrual bleeding for 12-60 months secondary to natural menopause, according to STRAW criteria48
- Hysterectomy without bilateral oophorectomy if surgery was completed after 6+ months of amenorrhea (no maximum duration of amenorrhea required)
- Bilateral oophorectomy (no minimum or maximum duration of amenorrhea required)
- Serum follicle-stimulating hormone (FSH) >25 IU/L and estradiol <20 pg/ml
- Diagnosis of major depression on the MINI
- Mild-to-moderate depressive symptoms, as indicated by MADRS score 15-31 and BDI score >15
- Normal mammogram within the past 2 years
- Good general health
Exclusion Criteria:
- Severe depression, defined as a MADRS score >31, psychotic symptoms, or suicidal or homicidal ideation
Psychiatric illness, as defined by clinical interview and the Mini-International Neuropsychiatric Interview (MINI), as:
- A lifetime history of bipolar disorder
- A lifetime history of severe depression, as characterized by current or prior psychotic symptoms, inpatient psychiatric hospitalization or a suicide attempt in the previous 5 years, or
- Current panic disorder or obsessive compulsive disorder
- A lifetime history of psychotic symptoms
- Current anorexia nervosa
- An alcohol or substance-use disorder active within the past year
- Current suicidal or homicidal ideation
- Previous diagnosis of a sleep disorder (sleep apnea, PLMS, etc) or diagnosed on a screening PSG study
- Pregnant, confirmed with serum ß-HCG at baseline (Visit 1)
- Breastfeeding
- Contraindication, hypersensitivity, or previous adverse reaction to E2 therapy
- Current or recent (1 month) use of centrally active medications (antidepressants, anxiolytics, hypnotics, anticonvulsants, stimulants)
- Current or recent (2 months) use of systemic hormone medications
- History of breast cancer, premalignant breast lesions, or undiagnosed breast mass
- Vaginal spotting or bleeding
- History of thrombo-embolism, cardiovascular disease, congestive heart failure or other contraindication to estradiol therapy.
- Liver dysfunction or disease
- Renal insufficiency
- Contraindications to progestin therapy
- Asthma, diabetes mellitus, epilepsy, and migraine disorders that are not stable and under medical management
- Other medical contraindications to estradiol and progestin therapy including porphyria, systemic lupus erythematosus, hepatic hemangiomas, deep vein thrombosis, hereditary angioedema, hypertriglyceridemia, severe Hypocalcemia.
Clinically significant abnormalities in screening blood tests including:
- Thyroid-stimulating hormone <0.50 or >5.0 uU/mL)
- Shift workers
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo control
|
Placebo control matched to estradiol tablets.
Daily dosing for one month.
|
|
Experimental: Estradiol
|
Oral estradiol 1.0 mg/day for four weeks.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Improvement of Mood, Measured by the Clinician-rated Montgomery-Asberg Depression Rating Scale (MADRS) From Baseline to Study End.
Time Frame: one month
|
one month
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Improvement of Mood, Measured by the Self-rated Beck Depression Inventory (BDI) From Baseline to Study End.
Time Frame: one month
|
one month
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2009p001776
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.